- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02915679
Pain Perception in Suicidal Behavior Vulnerability (DOCS)
In France, almost 1 death on 50 is a suicide. The suicide occurs in unbearable psychic pain where mental trouble has a major influence. It is classified as preventable mortality. According to interpersonal psychological theory of suicide, the repeated exposition to stressful and painful events (as physical abuse) would facilitate suicide attempt through the increased pain tolerance. The social pain (or psychical pain on the broader sense) and physical pain are closely linked.
The investigators hypothesize that the measure of painful perception will be significantly superior on suicidals attempters compared to non-attempters. It will be the case for recent suicide attempters and former suicide attempters, suggesting a suicidal vulnerability trait. Moreover, the investigators expect that social distress induced by a social exclusion paradigm will be significantly superior on suicide attempters compared to non-attempters.
The aim of the study is to investigate the physical and psychic pain on depressed subjects with or without history of suicide attempts.
After a clinical evaluation (psychiatric symptomatology, personality trait, suicidal dimension), subjects will be submitted to a painful thermic stimulation and will participate at a computer test of social exclusion (named Cyberball).
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
242 depressed patients ( 81 recent suicide attempters, 81 former suicide attempters, 80 non-attempters)
First visit : clinical assessment Second visit : pain evaluation and blood sample (from one day to a week maximum after the first visit).
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Montpellier, France, 34295
- Montpellier Hospital University
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion criteria:
- aged by 18 years old
- came from West Europe, excepted Basque and Sardinian (because of genetics analysis)
- main diagnosis of major depressive episode (DSM V criteria)
- not having take antalgics in the 24 hours before assessment
- received a minimal psychotrope treatment (clinician evaluation)
- Able to understand nature, aims, methodology of the study
- Agree to cooperate in clinical and biological assessment
- Having signed informed consent
Specific inclusion criteria :
81 recent suicide attempters (being hospitalised for suicidal attempts and having realised a suicide attempts 8 days before inclusion) 81 former suicide attempters (having realised in his lifetime a suicide attempt, one month before inclusion)
Exclusion criteria:
- Current diagnosis of manic, hypomanic or alcohol dependance or substance abuse in the last 6 months, or diagnosis of schizophrenia or schizoaffective disorder in his lifetime
- Current algic and chronic neurologic disease
- Current or actual treatment by tricyclic antidepressant and Serotonin and norepinephrine reuptake inhibitors(SNRIs)
- Pregnancy
- Patients on protective measure
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Other
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Other: Study participant
All the participants performed blood sample for genetic purpose, psychiatric assessment and pain investigation:
|
All the participant will performed the same evaluation and blood analysis:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Pain tolerance reported by the patient
Time Frame: During thermal stimulation
|
temperature measured when the subject will perceive as intolerable the pain following a painful stimulation performed using a thermode
|
During thermal stimulation
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Pain intensity reported by the patient
Time Frame: During thermal stimulation
|
comparison between the three groups of the pain intensity (assessed by likert scale) at constant temperature (43 ° C)
|
During thermal stimulation
|
|
Pain threshold reported by the patient
Time Frame: During thermal stimulation
|
comparison between the three groups of the pain threshold (temperature perceived as painful)
|
During thermal stimulation
|
|
Temperature assessed at 4/10 on likert scale
Time Frame: During thermal stimulation performed at the inclusion
|
comparison between the three groups of the temperature assessed at 4/10 on a visual analogic painful scale, kinetics of pain intensity by visual analog scale (VAS) scale.
|
During thermal stimulation performed at the inclusion
|
|
Kinetics of pain intensity
Time Frame: During thermal stimulation performed at the inclusion
|
comparison between the three groups of kinetics of pain intensity by visual analog scale (VAS) scale.
|
During thermal stimulation performed at the inclusion
|
|
Social distress perception assessed by social distress questionnaire
Time Frame: At V2 (one week maximum after the inclusion)
|
comparison between the three groups of the score of social distress scale after cyberball game
|
At V2 (one week maximum after the inclusion)
|
|
Social distress perception assessed by the Rejection Sensitivity Questionnaire (RSQ)
Time Frame: At the inclusion
|
comparison between the three groups of the score of social distress scale after cyberball game
|
At the inclusion
|
|
Social rejection sensitivity assessed by the Rejection Sensitivity Questionnaire (RSQ)
Time Frame: At the inclusion
|
comparison between the three groups of the score of social rejection sensitivity by RSQ
|
At the inclusion
|
|
Psychological pain intensity
Time Frame: At V2 (one week maximum after the inclusion)
|
comparison between the three groups of the score of psychological pain intensity assessed by VAS scale.
|
At V2 (one week maximum after the inclusion)
|
|
Measure of cardiac frequency in response to thermal pain
Time Frame: At V2 (one week maximum after the inclusion)
|
comparison between the three groups of the cardiac frequency.
|
At V2 (one week maximum after the inclusion)
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
- UF 9185
- 2013-A01029-36 (Other Identifier: Agence Nationale de Sécurité des Médicaments)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Major Depressive Episode
-
Assistance Publique - Hôpitaux de ParisNot yet recruitingSignature Response to Light Therapy in Unipolar and Bipolar Major Depressive Episode (MDE) (SoLuRep)Major Depressive EpisodeFrance
-
University Hospital, MontpellierRecruitingMajor Depressive EpisodeFrance
-
Medical University of ViennaUnknownMajor Depressive EpisodeAustria
-
The University of New South WalesWesley MissionUnknown
-
Northside Clinic, AustraliaWesley MissionCompletedMajor Depressive EpisodeAustralia
-
Jiangsu Province Nanjing Brain HospitalRecruiting
-
Jiangsu Province Nanjing Brain HospitalCompletedMajor Depressive EpisodeChina
-
Alto NeuroscienceRecruitingBipolar Disorder I or II With a Major Depressive EpisodeUnited States
-
Neumora Therapeutics, Inc.CompletedMajor Depressive Episode Associated With Bipolar II DisorderUnited States
-
Assistance Publique - Hôpitaux de ParisRecruiting
Clinical Trials on Blood sample for genetic purpose, psychiatric assessment and pain investigation
-
University Hospital, MontpellierInstitut National de la Santé Et de la Recherche Médicale, France; Sys2Diag...Completed
-
University Hospital, MontpellierAssistance Publique Hopitaux De Marseille; Centre Hospitalier Universitaire... and other collaboratorsRecruitingMajor Depression | Primary Care | Bipolar Disorder (BD) | Major Depressive Episode (MDE)France
-
Antonio SecchiCompletedKidney Transplant | Pancreatic Transplat | Pancreatic Islets LangerhansItaly
-
Fondazione IRCCS Ca' Granda, Ospedale Maggiore...RecruitingVon Willebrand Disease (VWD) | Acquired Von Willebrand DiseaseItaly
-
Hywel Dda Health BoardUniversity of AberdeenRecruitingDiabetic Macular Edema (DME) | Diabetic Retinopathy (DR) | Diabetic Retinopathy Associated With Type 2 Diabetes MellitusUnited Kingdom
-
University Hospital, BordeauxPfizerCompleted
-
Hospices Civils de LyonRecruitingAutoimmune Diseases | Genetic Disease | Autoinflammatory Disease | Systemic LupusFrance
-
Assistance Publique - Hôpitaux de ParisInstitut National de la Santé Et de la Recherche Médicale, France; URC-CIC...Active, not recruiting
-
Central Hospital, Nancy, FranceRecruitingAcute Heart FailureFrance
-
Assistance Publique - Hôpitaux de ParisNot yet recruitingCarcinoma, Non-Small-Cell Lung